ClearB Therapeutics Announces Upcoming Poster Presentations of Pre-Clinical Chronic Hepatitis B Data at EASL 2024

CONCORD, MA, 29 May 2024 — ClearB Therapeutics, Inc., a company developing CLB-3000, a therapeutic vaccine designed to drive a functional cure for Hepatitis B, announced today that two abstracts will be presented as posters at the European Association for the Study of the Liver (EASL) International Liver Congress (ILC) 2024, taking place in Milan, Italy 5 – 8 June 2024. In addition, one of the posters has been selected as a TOP presentation (see details below).

“While we are progressing our therapeutic vaccine candidate, CLB-3000, in first in human trials, we are excited to share preclinical data on other approaches we are pursuing with the Hepatitis B community” said Aileen Rubio, PhD, CEO of ClearB Therapeutics. “Chronic Hepatitis B (CHB) infection remains a substantial global health care problem in need of effective antiviral and immunomodulatory therapies. We believe that ClearB’s therapeutic vaccine and our other approaches could become an important component of combination treatment regimens.”

Abstract Number: SAT-339
Abstract Title: Sequential administration of siRNA with an mRNA encoding clearance profile associated variants of HBsAg exhibits significant antiviral activity in an AAV/HBV mouse model
Date: Saturday, 8 June 2024
Time: 9:00 AM GMT+1
Presenter Name: Dr. Aditi Deshpande, ClearB Therapeutics

Abstract Number: TOP-353
Abstract Title: An mRNA vaccine exhibits anti-viral activity in a mouse model of persistent Hepatitis B infection
Date: Saturday, 8 June 2024
Time: 9:00 AM GMT+1
Presenter Name: Dr. Aditi Deshpande, ClearB Therapeutics

For more information regarding the abstracts at EASL 2024 please visit : EASL Congress 2024 – OFFICIAL WEBSITE

About ClearB Therapeutics
ClearB Therapeutics was co-founded in 2017 by Morningside Ventures in collaboration with Professor Stephen Locarnini and the Victoria Infectious Diseases Reference Laboratory in Melbourne, Australia. ClearB is working to develop therapeutic vaccines designed to drive functional cure of hepatitis B. The work is grounded in proprietary insights derived from studying rare-event infection resolution in patients who suffer from chronic hepatitis B. For more information, please visit

About Morningside Ventures: Morningside was founded in 1986 by the Chan family, to make private equity and venture capital investments in North America, Europe, and Asia Pacific. In the life sciences, Morningside specializes in early-stage (pre-clinical through human proof-of-concept) investments in biopharmaceutical products. They partner with academic founders and entrepreneurs to build world-class companies that want to markedly improve the current state of medicine today and ultimately, the lives of patients. Morningside’s focus is to invest in excellent biomedical research, where a significant body of knowledge has been gathered and

there is a plausible path forward in clinical development. Their mission is to contribute to making a meaningful, positive impact on the prevention or treatment of human disease, and believe that so long as this is achieved, commercial success will follow.

ClearB Therapeutics, Inc. [email protected]